Asset Life Cycle Management focusing on recapitalization decision making by Gabriel Gimenes, Head Of Engineering and HSE at Novartis
In the context of pharma maintenance, the focus of asset life cycle management should be on ensuring that the assets are maintained in good condition to support the safe, efficient, and effective production of pharmaceutical products. One of the key decisions that must be made in this context is the decision to recapitalize an asset, which involves replacing or upgrading it to maintain its performance and extend its life.
This presentation covers:
– Technical feasibility
– Economic viability – Regulatory compliance
– Operational impact